Article Text

Download PDFPDF
508 The impact of the covid pandemic on cervical cancer stage in a tertiary gynaecological oncology centre
  1. Teresa Treacy1,
  2. Sarah Belton2,
  3. Edward Corry1,
  4. Jennifer Gilmore3,
  5. Ruaidhri Mcvey4,
  6. Donal O’Brien2,
  7. Osama Salib5,
  8. Claire Thompson1,
  9. Tom Walsh1 and
  10. Donal Brennan1
  1. 1Mater University Hospital, Dublin, Ireland
  2. 2St Vincent’s University Hospital, Dublin, Ireland
  3. 3St Luke’s Radiation Oncology Network and Mater University Hospital, Dublin, Ireland
  4. 4St Vincent’s University Hospital and Mater University Hospital, Dublin, Ireland
  5. 5St Luke’s Radiation Oncology Network and St Vincent’s University Hospital, Dublin, Ireland


Introduction/Background This study reviewed all cases of cervical cancer presenting to a tertiary Gynaecological Oncology centre in Dublin, Ireland from 2019 – 2022. The aim of this review was to assess the impact of COVID-19 restrictions in March 2020 patterns of presentation of cervical cancer.

Methodology This was a retrospective cohort study reviewing all cases of cervical cancer diagnosed from 2019 – 2022 inclusive. A review of all cases of primary cervical cancer from 2019 – 2022 was performed. Stage of disease was as per FIGO Cancer of the cervix uteri: 2021 update.

Results 341 patients were diagnosed with cervical cancer during this period, stage breakdown is presented in table 1. The median age at presentation was 45 years old (range 24–89), (74% squamous cell carcinoma (SCC)). There was a 26% reduction in the number of cancers diagnosed in 2020 compared to 2019 (67 vs 83). The proportion of Stage 1a1 cancers remained lower in 2022 compared to 2019 (19% vs 24%) and the proportion of locally advanced and metastatic cancer (Stage 2b-4b) increased from 50% in 2019 to 58% in 2022, with a stable overall incidence. The median age of those presenting with locally advanced and metastatic disease was 51 (range 24–89) (84% SCC, 12% adenocarcinoma).

Conclusion These findings outline a decrease in the proportion of early-stage disease following the COVID pandemic and an increase the proportion of women presenting with locally advanced or metastatic disease. These observations may be a result of COVID restrictions and their impact on screening services, as well as increased immigration to Ireland from eastern Europe which has higher cervical cancer incidence (20.3 vs 13.8 per 100000 women), no HPV vaccination program and lower uptake of screening services (57% vs 82%); highlighting the need to promote screening services in migrant and minority communities.

Disclosures Donal Brennan (DB): Receipt of grants/research supports: AstraZeneca, GSK, Pfizer, MSD

Receipt of honoraria or consultation fees: Medtronic, Bayer, GSK, Astellas, Olympus, MSD

Participation in a company sponsored speaker’s bureau: Bayer, GSK, Astellas

Abstract 508 Table 1

Incidence of cervical cancer based on FIGO stage

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.